ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Sunday, November 13, 2022

9:00AM-10:30AM: Abstract Number: 0669

Understanding How Type I Interferon Modulates Langerhans Cell ADAM17 to Promote Photosensitivity in Lupus

SLE – Etiology and Pathogenesis Poster

9:00AM-10:30AM: Abstract Number: 0729

Understanding the Practice and Process of Patient Reported Outcome Measures Collection in North American Pediatric Rheumatology Clinics: A Survey of the Pediatric Rheumatology-Care and Outcomes Improvement Network

Health Services Research Poster II

9:00AM-10:30AM: Abstract Number: 0955

Unfavorable Pregnancy Outcome Is Significantly Associated with Corticosteroid Exposure During Pregnancy in Women with RA: Analysis of the Prospective GR2 Cohort

Reproductive Issues in Rheumatic Disorders Poster

9:00AM-10:30AM: Abstract Number: 0744

University of North Carolina and Piedmont Health Collaborative Tele-Rheumatology Project to Optimize Rural Health Specialty Access

Health Services Research Poster II

9:00AM-10:30AM: Abstract Number: 0827

Unpublished Clinical Trials of Major Rheumatic Diseases

Miscellaneous Rheumatic and Inflammatory Diseases Poster II

9:00AM-10:30AM: Abstract Number: 0909

Unsupervised Clustering Analysis of Circulating Molecular Profiles in Rheumatoid Arthritis Patients Defines Precise CV Risk. Effects of TNFi, IL6Ri, and JAKinibs

RA – Diagnosis, Manifestations, and Outcomes Poster II

9:00AM-10:30AM: Abstract Number: 0928

Use of Disease Modifying Anti-rheumatic Drugs and Risk of Multiple Myeloma in US Veterans with Rheumatoid Arthritis

RA – Treatment Poster II

9:00AM-10:30AM: Abstract Number: 0969

Use of Gonadotropin-releasing Hormone Agonists for Ovarian Preservation in Patients Receiving Cyclophosphamide for Systemic Lupus Erythematosus: A Meta-analysis

Reproductive Issues in Rheumatic Disorders Poster

9:00AM-10:30AM: Abstract Number: 0745

Use of Telemedicine in Patients with Systemic Lupus Erythematosus in a Publicly Funded Hospital System

Health Services Research Poster II

9:00AM-10:30AM: Abstract Number: 0834

Use of the Routine Assessment of Patient Index Data 3 (RAPID3) Questionnaire in the Assessment of Chronic Lower Back Pain

Orthopedics, Low Back Pain, and Rehabilitation Poster

9:00AM-10:30AM: Abstract Number: 1057

Usefulness of REVEAL 2.0 Score as a Prognosis Tool of All-Cause Pulmonary Hypertension in Systemic Sclerosis Patients: A Multicentric Study

Systemic Sclerosis and Related Disorders – Clinical Poster I

9:00AM-10:30AM: Abstract Number: 0725

Utility of Repeat Extractable Nuclear Antigen Antibody Testing- a Retrospective Audit

Health Services Research Poster II

9:00AM-10:30AM: Abstract Number: 1043

Uveitis in Patients with Axial Spondyloarthritis or Psoriatic Arthritis: Baseline Characteristics and Incidence Rates During Secukinumab and Placebo Comparative Phase: A Post Hoc Analysis

Spondyloarthritis Including PsA – Treatment Poster II: Mixed

9:00AM-10:30AM: Abstract Number: 0703

Vaccination Against SARS-CoV2 in Patients with Systemic Autoimmune Diseases: A Safety Report from EULAR COVAX Registry

Epidemiology and Public Health Poster I

9:00AM-10:30AM: Abstract Number: 1022

Validation of the SPARCCRETIC E-Tool for Ensuring Scoring Proficiency of MRI Lesions in Axial Spondyloarthritis

Spondyloarthritis Including PsA – Diagnosis, Manifestations, and Outcomes Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].